141 related articles for article (PubMed ID: 38376572)
41. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
[No Abstract] [Full Text] [Related]
42. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
43. Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Iriyama N; Yuan B; Hatta Y; Horikoshi A; Yoshino Y; Toyoda H; Aizawa S; Takeuchi J
Oncol Rep; 2012 Nov; 28(5):1875-82. PubMed ID: 22940758
[TBL] [Abstract][Full Text] [Related]
44. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
[TBL] [Abstract][Full Text] [Related]
45. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
46. All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Tallman MS
Leuk Lymphoma; 2010 May; 51(5):745-6. PubMed ID: 20423285
[No Abstract] [Full Text] [Related]
47. Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Jiang Y; Ji L
J Int Med Res; 2020 Sep; 48(9):300060520959487. PubMed ID: 32993392
[TBL] [Abstract][Full Text] [Related]
48. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Au WY; Lang BH; Fong BM; Mao KJ; Tam S
Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
[No Abstract] [Full Text] [Related]
49. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
[No Abstract] [Full Text] [Related]
50. Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
Collinge E; Tigaud I; Balme B; Gerland LM; Sujobert P; Carlioz V; Salles G; Thomas X; Paubelle E
Medicine (Baltimore); 2018 Feb; 97(8):e9657. PubMed ID: 29465554
[TBL] [Abstract][Full Text] [Related]
51. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
52. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
53. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
54. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
55. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
[TBL] [Abstract][Full Text] [Related]
56. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
57. Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
Ravindranath Y; Gregory J; Feusner J
Leukemia; 2004 Oct; 18(10):1576-7. PubMed ID: 15356650
[No Abstract] [Full Text] [Related]
58. ATRA plus arsenic gets another "A" in APL.
Park JH
Blood; 2012 Aug; 120(8):1535-6. PubMed ID: 22918418
[TBL] [Abstract][Full Text] [Related]
59. Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Yamada Y; Osumi T; Kato M; Shioda Y; Kiyotani C; Terashima K; Hayakawa A; Iijima-Yamashita Y; Horibe K; Matsumoto K; Tomizawa D
J Pediatr Hematol Oncol; 2022 May; 44(4):178-180. PubMed ID: 35091516
[TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
